Core Insights - FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials [1][3] - The company holds over 270 patents issued and pending, covering various clinical pathways including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer [3] Company Presentation - The CEO, Pete O'Heeron, will present at the BIO Investment & Growth Summit on March 2-3, 2026, in Miami Beach, FL [1] - The company will have a presentation scheduled for 10:15 a.m. ET on March 2 and will be available for one-on-one meetings throughout the event [2] Company Overview - FibroBiologics is based in Houston and represents the next generation of medical advancement in cell therapy and tissue regeneration [3] - The company is actively developing a pipeline of treatments aimed at chronic diseases [3]

Core Viewpoint - FibroBiologics, Inc. has successfully closed a registered direct offering, raising approximately $4 million through the issuance of common stock and pre-funded warrants, with a unique payment method involving gold coins [1][2][4]. Company Overview - FibroBiologics is a clinical-stage biotechnology company focused on developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, holding over 270 patents [1][10]. - The company is engaged in various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer [10]. Offering Details - The company issued 3,540,000 shares of common stock and pre-funded warrants to purchase 8,570,203 shares at a price of $0.3303 per share [1]. - The purchase price was paid with sovereign-issued .9999 fine gold coins valued at $4,069.18 per ounce [2]. - In a concurrent private placement, unregistered warrants were issued to purchase up to 12,110,203 shares of common stock, with an exercise price of $0.3303 per share [3]. Financial Implications - The gross proceeds from the offering were approximately $4 million, intended for general corporate purposes, including debt satisfaction [4]. - If the unregistered warrants are fully exercised for cash following stockholder approval, the company could receive an additional $4 million [4]. Regulatory Compliance - The shares and pre-funded warrants were offered under a shelf registration statement previously filed with the SEC [5]. - The unregistered warrants were offered in a private placement and have not been registered under the Securities Act [6].